Incannex Announces Initiation of Research Coverage by Alliance Global Partners
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, announced that Alliance Global Partners has initiated equity research coverage with a BUY rating and an $18 target price. The coverage highlights Incannex's lead drug candidates IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder, emphasizing the comp…